Grunenthal Says Actavis, Alkem Infringed Painkiller IP
Actavis and Alkem allegedly violated the three patents by filing abbreviated new drug applications with the U.S. Food and Drug Administration to manufacture and sell tapentadol hydrochloride tablets for pain management before the patents' expiration, Grunenthal said
The generic pharmaceuticals manufacturers have "committed or aided,...
Already a subscriber? Click here to login